Diabetes hospitalizations and deaths in a cohort of treatment-seeking illicit drug users

Alex Aregbesola1, Ifeoma N Onyeka1, Olubunmi Olubamwo1, Kimmo Ronkainen1, Jari Tiihonen2,3, Jaana Föhr4 and Jussi Kauhanen1

Abstract

Background: Studies on diabetes among illicit drug users are scarce in Finland. This study aimed to describe hospitalization and death due to diabetes among treatment-seeking illicit drug users.

Methods: Information of 4817 treatment-seeking drug users (3365 men and 1452 women) aged 11–65 years (mean 24.5 years) was linked to the Finnish national hospital discharge register and the national death registry to identify those clients who were hospitalized or died from diabetes mellitus during 1997–2013.

Results: Fifty-three persons (42 men and 11 women) had primary diagnoses of diabetes, with a total of 146 hospitalizations (121 among men and 25 among women). The total length of stay among men (1183 days) far exceeded those of women (138 days). Overall, type 1 diabetes was the main contributor to hospitalizations (67%, n = 98/146). The proportion of Type 1 diabetes with complications was 31% in men (n = 37/121) and 44% in women (n = 11/25). All cases of deaths due to diabetes (n = 7) occurred in men.

Conclusion: Diabetes hospitalizations were mainly due to Type 1 diabetes. Longer length of hospital stay was observed in men, and all diabetes deaths occurred among men. Male drug users and drug users in general would require more support to reduce morbidity and mortality due to diabetes.

Keywords
Diabetes mellitus, hospitalizations, deaths, substance abuse, register linkage, cohort study, epidemiology

Date received: 25 July 2017; accepted: 8 March 2018

Introduction

Diabetes and its complications among illicit drug users have been reported in different population samples.1–3 Hospitalizations due to diabetes ketoacidosis (DKA) and other known diabetes complications have been linked to substance abuse. A recent study carried out in a Spanish population suggested that illicit drug use may have a role in diabetes-related hospitalization.5 Likewise, a study among Polish adolescents found that cannabis use was associated with a poorer glycemic control among teenagers with Type 1 diabetes.3 Reports from Umpierrez et al.5 and Warner et al.6 showed that cocaine use is related to some of the adult DKA admissions. However, Modzelewski et al.’s study7 found no association between active cocaine use at the time of hospital admission and development of hyperglycemic crisis. Omission of insulin therapy by people with diabetes is directly associated with acute and increased hospital admissions due to DKA and other diabetes-related hospitalization.8 Several factors were examined in a multi-ethnic study which evaluated the precipitating factor for frequency of intentional skipping of insulin injection but illicit drug use was neither investigated nor reported.9 A US-based study which investigated the causes of insulin therapy cessation among DKA

1 Institute of Public Health and Clinical Nutrition, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
2 Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland
3 Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
4 Helsinki Deaconess Institute, Helsinki, Finland

Corresponding author:
Ifeoma N Onyeka, Institute of Public Health and Clinical Nutrition, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, Kuopio FI-70211, Finland.
Email: ifeoma.onyeka@uef.fi

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Diabetes-related mortality is also on the increase among this subpopulation of illicit drug users. Neglect in taking the history of recreational drug use among people with diabetes, and especially among those with a history of frequent hospitalization, has been suspected as a possible explanation for the adverse profile in this subpopulation. A recent study by Jacobsen et al., which reviewed the terminal hospitalization records of organ donors with Type 1 diabetes, showed that anoxia secondary to illicit drug overdose was the leading cause of death. Furthermore, a case report of a 19-year-old woman with diabetes who used ecstasy and alcohol and was later found dead the following day provided further grounds for concern regarding diabetes mortality in this subpopulation. It is therefore important to focus resources on the management of substance abuse problems. In the general population, age, male gender, education, income, and presence of comorbidity have been associated with non-adherence to oral anti-hyperglycemic agent use among people with Type 2 diabetes. In Type 1 diabetes, diet non-adherence is a more prominent risk factor for insulin omission. However, little is known about the influence of these factors among illicit drug users with diabetes.

In Finland, data on hospitalizations and deaths due to diabetes among illicit drug users are scarce. Some researchers had previously investigated the association between substance use and diabetes, and the focus of their research was the association between alcohol consumption and Type 2 diabetes. However, their study samples (Finnish Twin Cohort) were not drawn from a drug-using population and there was no information about illicit drug users. To the best of our knowledge, we are not aware of any study that has investigated diabetes morbidity and mortality among illicit drug users. We therefore described hospitalization and death due to diabetes among illicit drug users.

**Methods**

All Finnish citizens and permanent residents have a unique personal identification number that makes it possible to perform linkage to health and administrative registers at individual level. The study population comprised 3365 men and 1452 women who sought drug abuse treatment at the Helsinki Deaconess Institute (HDI) during 1997–2008. Their primary drugs of abuse reported at initial clinical consultation at HDI included opiates, stimulants, cannabis, medication, alcohol, and other drugs. Detailed descriptions of the study population and data collection method have been provided elsewhere. Clients’ information was linked to the national hospital discharge register and the national death registry, and they were followed-up to December 2013 or death, whichever came first, in order to identify hospitalizations and deaths, respectively. In both registers, diagnoses were recorded using the 10th version of the International Classification of Disease (ICD-10) codes. This study considered only a subset of the clients whose main/primary hospitalization diagnoses and whose underlying causes of death were recorded as ICD-10 codes E10–E14 denoting diabetes mellitus.

Statistical Package for Social Sciences (SPSS) software version 21 for Windows (IBM Corporation, Armonk, NY) was used for all analyses. Data were presented as frequencies, proportions, means, and standard deviation (SD). The research ethics committees of the Kuopio University Hospital and the HDI, the Ministry of Social Affairs and Health of Finland, and appropriate municipal authorities gave approval for the study.

**Results**

**Baseline characteristics**

Of the 4817 clients, nearly all of them (98%) were Finnish citizens. Seven out of 10 clients (70%) were men and 30% were women. The mean age of the clients was 24.5 years (range: 11–65 years, SD 8.1). Out of the 3784 persons with complete data for marital status, 84% were not married, 8% were married/cohabiting, and 9% were separated/divorced/widowed. Their primary drugs of abuse reported at baseline/initial clinical consultation included opiates (30%) mainly heroin and buprenorphine, stimulants (28%) mainly amphetamines, cannabis (19%), alcohol (21%), prescription medication (2%) mainly benzodiazepines, and other drugs (1%). A more detailed description of the baseline characteristics of the entire cohort can be found elsewhere.

**Diabetes hospitalizations**

Individual ICD-10 diagnoses and the observed numbers of hospitalizations are shown in Table 1. Information from the national hospital discharge register revealed that 53 persons had primary diagnosis of diabetes at the end of 2013. Of these, 42 were men and 11 were women. These 53 persons accumulated a total of 146 hospitalizations, 121 among men, and 25 among women. Overall, hospitalizations for Type 1 diabetes were higher than Type 2 diabetes and accounted for 98 out of the 146 hospitalizations (Table 1). Of the overall 98 hospitalizations due to Type 1 diabetes, 48 were with complications and 35 of these complications were DKA. In terms of gender, the number of Type 1 diabetes with complications was higher in men (37 hospitalizations) than in women (11 hospitalizations). However, the proportion of Type 1 diabetes complicated by DKA was higher in women (10 of 11 hospitalizations) than in men (25 out of 37 hospitalizations). The total length of hospital stay in men (1183 days) far exceeded those of women (138 days).

**Diabetes deaths**

Deaths in the cohort due to diabetes are presented in Table 2. Information from the national death registry revealed that a total of seven deaths had occurred by the end of 2013. All deaths occurred among men and they were due to
complications such as coma, ketoacidosis, and multiple complications.

**Discussion**

This study described the diabetes and diabetes-related hospitalizations and mortality among 4817 clients who sought drug abuse treatment at HDI. It showed that Type 1 diabetes and its related complications were the main contributors to hospitalization. Men had more primary diagnosis of Type 1 diabetes, higher total number of diabetes-related hospitalizations, and accumulated higher total length of hospital stay than women. Type 2 diabetes contributed one-third of the hospitalizations. All deaths from diabetes occurred in men.

Given the mean age of our cohort, this finding is in keeping with what obtains in the general population in which more cases of Type 1 diabetes are known to occur more among young adults. It is known that non-compliance or omission of insulin therapy is strongly associated with poor glycemic control in Type 1 diabetes and this often leads to acute hospital admission with or without complication. Alcohol and other substances of abuse have been suggested by some authors as the contributing factors to poor insulin therapy compliance. Although cannabis, tobacco, and cocaine use were all associated with non-compliance with insulin therapy in Nyenwe et al.’s study, they found that cocaine use was an independent risk factor for having more DKA-related admissions. In a similar vein, a higher proportion of those with primary diagnosis of diabetes in our study reported stimulants as the primary drug of abuse compared to the other members of the cohort (45.3% vs 27.5%, respectively), followed closely by opiate use (32.1% vs 29.7%, respectively, data not shown). However, Modzelewski et al.’s study found no association between active stimulant/cocaine use at the time of hospital admission and development of hyperglycemic crisis. Apart from insulin omission, there may be other potential mechanisms for hyperglycemic crisis. Drug users tend to have poor health. The presence of infections and other morbidities could trigger secretion of counter-regulatory hormones that promote hyperglycemia.

Two previous studies that examined illicit drug use among people with diabetes reported conflicting results. Although information about the hospitalization status of the Chilean participants in Martinez-Aguayo et al.’s study was not provided, they found a lower lifetime rate of use of illicit drug among adolescents with diabetes when compared to the general population without diabetes. However, a Spanish study by Isidro and Jorge found that the frequency of illicit drug use was higher among people with diabetes.
Deaths due to diabetes are a significant issue for patients with Type 1 diabetes. The cohort consisted of treatment-seeking drug users and our findings may not be generalizable to non-treatment seekers. There were disproportionately affected and this might reflect the fact that male clients far outnumbered females in this cohort. That said, more effort is needed to address drug abuse problems in order to reduce morbidity and mortality due to diabetes. Furthermore, toxicological screening of illicit drug use among patients with history of frequent readmissions following diabetes complication could prove useful in early recognition of illicit drug use as a risk factor for diabetes complications and hospitalization; this early recognition with appropriate treatment will help in reducing the diabetes-related morbidity and mortality. In addition, educating patients on the need to adhere to diabetes treatment and on the potential health hazards of substance use in hyperglycemia may also help to reduce diabetes complications and hospitalization. Further studies with larger samples and extensive adjustment for known confounders of diabetes are needed to assess the contributions of each type of illicit drugs to morbidity and mortality due to diabetes among this subpopulation.

### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Ethical approval

Ethical approvals were obtained from the Research Ethics Committee of the Kuopio University Hospital and the Ethics Committee of Helsinki Deaconess Institute. Permissions were obtained from the Ministry of Social Affairs and Health of Finland and from appropriate municipal authorities of all Greater Helsinki area communities where clients resided.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the Academy of Finland (Grant Number 118584). The authors thank the staff members of the Helsinki Deaconess Institute for their collaboration, and the data managers at the University of Eastern Finland.

Informed consent
Informed consent was not necessary because Finnish legislation permits the use of medical records (without personal identifiers) for medical and health research with permission from government/institutional authorities.

ORCID iD
Ifeoma N Onyeka https://orcid.org/0000-0002-5351-1037

References
1. Martinez-Aguayo A, Araneda JC, Fernandez D, et al. Tobacco, alcohol, and illicit drug use in adolescents with diabetes mellitus. Pediatr Diabetes 2007; 8: 265–271.
2. Kaye S, Darke S, Duflou J, et al. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 2008; 103: 1353–1360.
3. Isidro ML and Jorge S. Recreational drug abuse in patients hospitalized for diabetic ketosis or diabetic ketoacidosis. Acta Diabetol 2013; 50: 183–187.
4. Hogendorf AM, Fendler W, Sieroslawski J, et al. Breaking the taboo: illicit drug use among adolescents with type 1 diabetes mellitus. J Diabetes Res 2016; 2016: 4153278.
5. Umpierrez GE, Kelly JP, Navarrete JE, et al. Hyperglycemic crises in urban blacks. Arch Intern Med 1997; 157: 669–675.
6. Warner EA, Greene GS, Buchsbaum MS, et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med 1998; 158: 1799–1802.
7. Modzelewski KL, Rybin DV, Weinberg JM, et al. Active cocaine use does not increase the likelihood of hyperglycemic crisis. J Clin Transl Endocrinol 2017; 9: 1–7.
8. Morris AD, Boyle DJ, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997; 350: 1505–1510.
9. Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care 2010; 33: 240–245.
10. Musey VC, Lee JK, Crawford R, et al. Diabetes in urban African-Americans. I. Cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis. Diabetes Care 1995; 18: 483–489.
11. Jacobsen LM, Haller MJ, Parish A, et al. High illicit drug abuse and suicide in organ donors with type 1 diabetes. Diabetes Care 2017; 40: e122–e123.
12. Gilbert JD and Byard RW. Fatal diabetic ketoacidosis—a potential complication of MDMA (ecstasy) use. J Forensic Sci. Epub ahead of print 2 August 2017. DOI: 10.1111/1556-4029.13602.
13. Zhu VJ, Tu W, Rosenman MB, et al. Nonadherence to oral antihyperglycemic agents: subsequent hospitalization and mortality among patients with type 2 diabetes in clinical practice. Stud Health Technol Inform 2015; 216: 60–63.
14. Carlsson S, Hammar N, Grill V, et al. Alcohol consumption and the incidence of type 2 diabetes: a 20-year follow-up of the Finnish twin cohort study. Diabetes Care 2003; 26: 2785–2790.
15. Onyeka IN, Uosukainen H, Korhonen MJ, et al. Sociodemographic characteristics and drug abuse patterns of treatment-seeking illicit drug abusers in Finland, 1997–2008: the Huuti study. J Addict Dis 2012; 31: 350–362.
16. Gale EA and Gillespie KM. Diabetes and gender. Diabetologia 2001; 44: 3–15.
17. Kovacs M, Charron-Prochownik D and Obrosky DS. A longitudinal study of biomedial and psychosocial predictors of multiple hospitalizations among young people with insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 142–148.
18. Skinner TC. Recurrent diabetic ketoacidosis: causes, prevention and management. Horm Res 2002; 57: s78–s80.
19. Nyenwe EA, Loganathan RS, Blum S, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract 2007; 13: 22–29.
20. Harjutsalo V, Forsblom C and Groop PH. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ 2011; 343: d5364.
21. Lee P, Greenfield JR and Campbell LV. Managing young people with type 1 diabetes in a “rave” new world: metabolic complications of substance abuse in type 1 diabetes. Diabet Med 2009; 26: 328–333.
22. Kaye S, McKeatin R, Duflou J, et al. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007; 102: 1204–1211.
23. Walters JM, Ward GM, Barton J, et al. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes. Metabolism 1997; 46: 1448–1453.
24. Gerich JE, Lorenzi M, Tsalikian E, et al. Studies on the mechanism of epinephrine-induced hyperglycemia in man. Evidence for participation of pancreatic glucagon secretion. Diabetes 1976; 25: 65–71.